pi-3k-in-22

PI3K-IN-22 is a dual kinase inhibitor of PI3Kα and mTOR, with IC50s of 0.9 and 0.6 nM respectively. PI3K-IN-22 could be used in cancer.

Ergosta-4,6,8(14),22-tetraen-3-one exhibits cytotoxic activity against human gastric cancer cells and can induce G2 M cell cycle arrest and apoptosis in human hepatocellular carcinoma (HepG2) cells. These findings could facilitate the further use of various medicinal fungi in cancer treatment.

S-Allylmercaptocysteine HCl is an organosulfur compound isolated from aged garlic with anti-inflammatory, antioxidant, anticancer, and antitumor activities.S-Allylmercaptocysteine HCl inhibits inflammation in COPD and targets Nrf2 in osteoarthritis therapy through the NOX4 NF-kappaB pathway. Targeting Nrf2.

22-Hydroxy-3-oxoolean-12-en-29-oic acid is a useful organic compound for research related to life sciences and the catalog number is T125847.

22-Hydroxy-3-oxo-12-ursen-30-oic acid is a natural product for research related to life sciences. The catalog number is TN2812 and the CAS number is 173991-81-6.

Heterocyclic compounds as covalent inhibitors of G12C mutant K-Ras protein useful for treating cancers.K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

K 259-3, a methyl ester of K 259-2, is an inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase.

K-Ras-IN-3 (compound 3) is an effective inhibitor of GDP-KRAS G12V, exhibiting an IC50 value of 0.371 nM. It has potential for use in cancer research.

K-Ras ligand-Linker Conjugate 3 (Compound 001371) is a chemical compound comprising a ligand for the K-Ras recruiting moiety and a PROTAC linker, responsible for recruiting E3 ligases (e.g., VHL, CRBN, MDM2, and IAP). This compound is essential for synthesizing PROTAC K-Ras Degrader-1, a potent degrader with a degradation efficacy of ≥70% in SW1573 cells[1].

Cathepsin K Inhibitor 3, exhibiting an IC50 value of 0.5 nM, is a highly selective inhibitor of cathepsin K, featuring a favorable pharmacokinetic profile. It holds potential for use in studies of osteoarthritis (OA).

PI3Kα-IN-22 (Compound 17) is a potent, selective, and orally active inhibitor targeting the PI3Kα H1047R mutation, exhibiting an IC 50 of 1 nM in the pAKT T47D AlphaLISA assay. It has demonstrated the ability to induce tumor regressions in the HCC1954 tumor model in mice [1].

3-Oxo-hop-22(29)-ene, a yeast α-glucosidase inhibitor, demonstrates moderate efficacy against the viability of T. cruzi and L. mexicana, and exhibits marginal anti-inflammatory activity.